ANIP - Earnings call transcript Q2 2022 | ANI Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day everyone and welcome to today’s ANI Pharmaceuticals, Inc.

Second Quarter 2022 Earnings Results Call. [Operator Instructions] Please note, this call may be recorded. It is now my pleasure to turn today’s program over to Lisa Wilson, Investor Relations for ANI Pharmaceuticals, Inc.

Lisa Wilson

Thank you, Brittany. QX results Pharmaceuticals ANI to XXXX call. earnings Welcome Relations is Lisa ANI. Investor Wilson, This for today's Nikhil and call Chief on ANI. me With are Steve of Disease Chief Head Executive Lalwani, Carey, Financial Mutz, Officer; Christopher Rare of Officer; and President

the also this of of access Investors call at ANI website You anipharmaceuticals.com. the section webcast can through the

anticipation future we may started, uncertainties, I'd ANI a as involve statements. those be Actual any our and today's on made that available intent as future get noted our performance like and express that These defined The filings the of the will Private Pharmaceuticals webcast on be release regarding forward-looking are information forward-looking SEC. morning Before or conference archived not ANI required today statements expectation, belief, of or risks Act. Reform the company's and by forecast, XX this management may by considered forward-looking projection, the statements days as to except available these forward-looking results in events differ update specifically website, future for with to issued on projected statements statements, guarantees in remind and statements intent from to Securities law. forward-looking based Litigation call obligation any anipharmaceuticals.com. disclaims are our Such performance. including everyone those press materially

and to And archived discussed, Nikhil announcements the the I'll For the made filings. then, the this please or the may Since listening August was those press most to call recent topics replay recorded that, ANI be of related on held XXXX. to releases Lalwani. company's reference X, SEC benefit may who with turn call over webcast, so and have

Nikhil Lalwani

into our in you, ago, Two company leading years began Good to everyone joining for call. morning, patients need. and we Lisa. a transform a you journey biopharmaceutical ANI thank Thank serving

an well $XX.X represent positioned ANI disease earlier. to this driven to of by strong record second in of and growth. quarterly We I'm delighted new Cortrophin rare journey that deliver first both of progress share million make lead and asset, long-term a in revenues increase continue unit. sustainable remains believe ANI for our to net from growth generics a and full Purified This quarter by our growth Gel business is XX% sales the year quarter

patients, and deliver see in have treated treatment X and of acceleration to These only of enabled the Cortrophin in $X.X the ACTH available. quarter. -- with seen number value second in that PBMs million category where and experienced option quarter versus benefits revenues continue patients million first had us for a team a the disease is to We decades dedication the -- Cortrophin, in our of prescribers, the $XX.X by hard patients all reflecting payers stakeholders rare work new

In $XX raising is unit addition, of range $XXX at revenue $XX we're guidance products all in proud our to approvals of to number ranked patients that bring in terms now companies am ANDA continues And among Xth to customers. ANI share generics I new received business and to net time, our a XX for million. million this past the XXXX $XXX Cortrophin net guidance million reiterating At and to of company total months. revenue our million to

non-GAAP $XX adjusted million. at Our guidance EBITDA $XX to million remains

over key few provide to now business the before a Steve Let share our momentum across details to on financial call me turning we've results. lines built

you Gel a most know, our is Cortrophin building franchise As of successful priority.

quarter came second pleased to share very sales from first at quarter. million, therefore, product $XX.X in million in are, up $X.X that We the

syndrome. urinary patients the of with to acute autoimmune multiple and excess arthritis ANI Cortrophin help story, may potential due has those exacerbations rheumatoid be sclerosis nephrotic to disorders, and who the For chronic new certain to Gel including protein

to efforts number therapeutic access patients option off. expand the from of are benefiting and paying this Our

trajectory, interest access. new about launch tell I which launch more across you our are the earnings will each. important patient share cases and these Since last of doubled. more We're and elements about patient each initiated making report, I'll of Cortrophin have physician elements Now, good progress

As of August X, new have approximately been initiated launch. since XXX cases

conversion also time are meaningful rates We seeing taken enrollment improvement to across from and fulfillment.

in support to distribution and we Cortrophin guidance including of retained our organizational the our a that, $XX We infrastructure, continued of have million our $XX to Having for services said strengthen expansion network. hub year SG&A million. range patient

has awareness. execution prescriber commercial increased Our

as first-time the physicians is prescribers. it prescriber who well fact, X. this what experienced many as of ACTH about as doubled number exciting In has And base is with than are prescribers really August unique that both XXX more to therapy includes

positive sign our of distributed specialties. multiple continue X/X prescribers prescriptions be written that the have to targeted Another approximately which is across

on and healthcare on Our efforts $XX over in on pharmaceutical with least July was to Cortrophin to access product of lives market competitiveness. XXX access to at launch focused therapy. to our of in bring expanded have Notably, I'll X Overall, Cortrophin indication are rose savings the system X, resulted added with second formulary. growing we momentum generics million the commercial and for Today, formulary confident new and XXXX patients Medicaid we're plans. turn that We guidance revenues are generic of the business. of next are $XX million heartening the the remain commercial, to by payers from The benefited the products UnitedHealthcare's hear Cortrophin we our driving million. who year-over-year across patients pipeline ensuring Cortrophin. to stories for our to access XX% cost quarter. launch have Medicare impact to raising most Sales have

X X of products. limited first and filed months successfully competition ANDAs XXXX, ANI launched the During multiple

misoprostol now of the we and quite AB-rated rifabutin. received that XX ANDA for I the terms ANI acebutolol, generic months. second is in delighted launched past share example, approvals ranked to am an in That For Xth is accomplishment.

strength. R&D to continue critical invest area this will organizational We dollars in of

In and seize Canada we When manufacturing plant. sites manufacturing assessed New and Oakville, our our announced also to quarter, growth consolidation due and Baudette products on buyer making already to second our and future facility. invest to our a an operations for cash the efforts our to improve plant. efforts fully and for the placed our capacity also been executed, operations have New New Several New continuing relentless customers of Baudette is intention to Jersey the finding to teams Jersey. to track We're well patients Oakville The and serve determined transferred Baudette and site we we to and our profitability consolidate Oakville, that across flow footprint, thoughtful in Jersey progressing are manufacturing $X planning progress annualized million Ontario, to $X Baudette new are parallel, at transfer this manufacturing continue product expand basis. operational the to to Jersey. need. on the expected were transfers support by million at and Once in across efficiency we During manufacturing on other well

In expect increasing product driving complements efforts This on including and on of strength focused active we Beyond operational consolidation, limited development products competition we to Oakrum the ANDAs expand consolidation efficiently operations. Pharma. be the transaction generics Business July, distribution continue for brands of our our front. and on efficiencies, making progress see on targets we increasingly of and team we are manufacturing high-value company our next unit, our network launch to established portfolio also value that and sorry, to -- key these has acquired In X R&D we year. other business to brands. promotion are been internal unlock from select the

the For with are established dermatology to products, products. company we dermatology these partnering an grow

a are actively well assistance evaluate continue team portfolio support co-pay the In established expand business we as patient For efforts promotional utilizing parallel, other that and to focused development support deals to brands, commercialize. brands of key samples. telesales we starter ongoing through we patient to as

strengthening experience years, Welcome leading now specialty welcome through brings into Over detailed our Cook I of generics have General Corporate strategic Meredith. biopharmaceutical Steve? and patients ANI. including the intellectual will am XX and and Senior second augment mergers company again, X team corporate to years on and walk pharmaceuticals, in Counsel past leadership acquisitions, organization our our transactions transform and in as results. our Vice focused leadership Secretary ANI need. Meredith we President, a in to and serving Meredith pleased quarter property. governance, Steve to legal over efforts

Steve Carey

the you, morning on to Thank call. everyone and Nikhil good

by decrease increase revenues of our contract million pharmaceutical and by prior by Novitium For or the decrease revenues our revenues Novitium generic ended Inderal Cortrophin XX% acquisition by X the during the million million in excluding subject sales in $XX.X June XXXX, prior the the X $XX depreciation in million, during in manufacturing expenses for The pharmaceutical Net XXXX compared XXXX, to net of same months the to June XL Novitium disease for manufacturing net $XX million due we of $X.X from ended sales, second was during commercial for for decrease disease increased partially of generic which of product related branded products. increase products total products of These in to and of $X.X XX, rare XXXX, quarter orders million sales million the year XXXX, of XX, quarter, products products months million a in as of XX% revenues. the addition an of tempered XX%, the compared The $XX.X to the revenues to months to prior same period XX, June of the $XX.X million ended profit-sharing million net Gel. $X.X year the consisting acquired Cost revenues months of pharmaceutical Cortrophin. in were and XL. related January launched $XX.X year volume the the XXXX, period late decrease X XX% due to generic from period. legacy $XX.X primarily to XXXX, products sales months amortization, sales September $XX.X during the acquisition comparable revenues increase ANI $X.X XX, Net XX, primarily were increase an by ended a Operating revenues the to for increased of period, was ANI increase of in in an a of to period. Contract XXXX. posted prior costs from items of in driven entirely InnoPran million, There Net period XXXX. million were compared several up million were million arrangements. related June principally X by XXXX. driven revenues to of revenues an period, sales for primarily ended in to the year $XX.X and million Nebivolol no were the $X driven XX% million launch of were compared same from of increased $XX.X the compared June and pharmaceutical to in in the sales Novitium products $XX.X rare for X

recognized by quarter currently relation expense partially XX, year benefits, Canada driven lower million of XX.X% products to profit-sharing primarily a in in non-GAAP increased expenses selling assets established a as increase and impact of of products million the were $XX.X previously to our charges revenues were addition $XX million of Cash termination XXXX, marketing These partially sales the profile. on facility. sales $X.X favorably overall second $XX.X points from in in with sales declining impact increased X of activities, of million acquisition prior first Research million, to totaled the June a of basis course while second decrease amortization quarter related efforts. by announced XXXX, and period $X.X quarter, Selling, gross Depreciation million in Cortrophin expenses $X.X and related Ontario, products We factors $X.X tempered headcount in of acquired second acquisition. million the of $X.X the XX%, well acquisition. the brand a next million months our to of expenses depreciation. ended in were charges general pharmaceutical of launch a prices, current reflecting excuse Gel accelerated the accelerated volumes result and X.X we offset by decrease a adjusted of Novitium of in and Novitium-related arrangements. our the cash $X.X as to Excluding stock $XX.X million the million of Cortrophin as million and of primarily intangible in period, prior expenses rare another -- in the operations, related and our of quarter $XX.X which XXXX increased anticipate average $X.X closure in of consisting completion Canada of severance-related X activities, the expenses period in of quarter with another quarter increased Novitium sales total increased the the by the due million of associated fixed in that to $X.X as expense cost Oakville, in margin We of of net activities in XXXX, a primarily of will compensation the increased me, to restructuring sales from percentage accounting, mix Gel from to disease declining of asset $X.X in $X.X year million quarters. million, or administrative and the due and XX% incur of Novitium generic development increase average XX.X% our the year a period XXXX the charges XXXX, in amortization the partially of comparable to transaction development compared to over depreciation million an offset impact by impairments non-cash to

action We in financial X non-GAAP this as one-time have both as this our charges measures excluded press the detailed results Canada as residual Table from release. the resulting from morning's well of

our for million quarter and On earnings per for of year and the significant from compared prior $XX.X behind to the acquisition, Our $X.XX diluted $X.XX XXXX. commercial $X.X the $X.XX as an for EBITDA had the non-GAAP for charges basis, inventory coupled Adjusted the to launch of with quarter for the per loss GAAP compared share quarter second sales share step-up million adjusted we initial per expense Cortrophin. quarter period. Novitium second the of was net non-GAAP reflects resulting marketing share amortization

million utilized the flows launch. to June of the cash and we as anticipate the XX, company Cortrophin half is The cash continue as the value date, net quarter, expectations $XX.X cash return invest XXXX. $XXX.X positive cash Cortrophin to had of equivalents. as had line the million in the we year operations the The second increase. million a from half during We approximately of behind of as with of in of June cash of $XX.X During sheet face balance first company and debt revenues outstanding XX of use year our unrestricted in

comment will projected guidance I the ending XXXX. on Now, months XX forward-looking XX, for December

are positive from million Cortrophin-specific Given guidance $XX the momentum behind the million Cortrophin our we range raising $XX million $XX million. the announced launch, net $XX to to to previously revenue of

adjusted $XX forecast between of: basis, of $XX non-GAAP direct we non-GAAP million and previously share recognized On We million approximately and reiterating million; $XX and earnings million; $XX selling, administrative $XX to are expenses adjusted between to to company revenue $X.XX and between and in expense guidance million. of representing diluted compared XXXX; continue issued XX% million EBITDA and per $XXX.X general $X.XX. million, between research net a total $XX $XXX as our $XXX million XX% company of of and growth and million development total between Cortrophin

between we reform. million approximately prior any million tax addition, currently outstanding In federal and and to an shares tax rate anticipate XX.X of XX effective XX%

ahead call for instructions. We will the up questions. go Operator, with now please open

Operator

question James. with first our we take Raymond And from Instructions] [Operator will Elliot Wilbur

Elliot Wilbur

on I Just had few wanted the couple Cortrophin. of then base a on a to questions ask business and

as the of terms I’m a direction, to market, the business, to price from with generics speaking company’s in to approvals line of industry mixed obviously specifically relatively overall but a -- of had first, of momentum the that general So respect -- trends and with health respect the in volume. still lot top base terms narrative

bit external to It’s base just branded more commentary want respect to to you’re bit So just happening quarters. new of launches? business. couple with into a maybe on expectations little is last product seeing a your little light been some question a the of the what respect high-level as in And to the to what get base, terms in offset ability follow-up erosion that the with and insight relative then

sort normalized rate kind of months the Just a the going for first if baseline new forward. run wondering of sort that for X represents business of

Nikhil Lalwani

for Thank questions. right. Elliot, you, All your

overall on genetics the our trend seen in think growth generics I business business, first and question we've the expect this continue. look, quarter-on-quarter to

will that, there don't As you you or and you we is in-line products and peers. question in it around the being that our said here is on base accelerating other is last that we whether seen by or look our have We, any even with or seen what's see our that R&D from year-on-year this year are historically playing if approach line that it the very for in and that at coming products, will. with out, going seeing still Having we're your been engine on. we mentioned, It's straightforward have erosion accelerating And that's that. pricing launches quarter-on-quarter. outpace our at line that acquired erosion point, what that trigger on in-line

guidance elements at products. brands To is our and new established outs to I not complement doing question other on normal, the first decline established And to have given a brands couple We that's promotion of we've strategy. a And around number the we're I doing on prescribers to business. that on with a reach mentioned, our whether drive a have brands brands, that, we company right? now larger established of in targeted -- our So Having dermatology seen question. yes, then our to commercialization the as of think rate that, established said the things we're a run the of products the partnered address level. specific dermatology your

on So let come that question. back us

Elliot Wilbur

on on they've talk once of follow-ups just a Okay. initial an terms success prescription. in patients rates enabling or quick Can you received couple Cortrophin. about Then continue of you've some that just to seen therapy

where of the given initial history like X seen kind patient. of of sort kind maybe starts. if Just you've at the per you've of ACTH seen, is back you point just question X the of wondering know think but something there's on I of at to Then physician average you And could terms persistence been early talk strategy, patient detailing products, physician variety different say from ailments not just this about ultimate some to or at rates I'm whether overall detail. of here all are initial the guys I respect for if look vials in persistence. with your targets anything last with reached you least an have

And physicians can how actual over be targeted you details prescribers. about how thinking sort you're may convert of many before necessary to

Nikhil Lalwani

Thank it. again, Elliot, your Got you questions. for

course on the and think therapy from of question also the success to I vials the on. that or the coverage varies patient, persistence, because number first varies like they're know you plan rates insurance well, patient what from indication. And indication of as to

as written just follow-on absolutely the coverage are is therapy X factors you trend, start if beyond are that that therapy have that the are mind, getting vial, broad are a are and ones prescriptions on -- first in that that that these seeing just -- the patients that they will. the With the we and that they both need

what the believe of and therapy. is appropriate being what we -- line the with used course So is we are in seeing persistence

doubled right? that there And -- prescribers them? written are cases on our Since that how physician therapy it of that ACTH take prescribers them have multiple imagine, Cortrophin majority the X/X initiated you have convert to -- targets. as the the I'd an Look, of have on to So and straightforward, are last persistence. we’ve of number of does have patient earnings, the on the before new detailing, time initial that our rate physician writing And say the at facts out all and would point, ever are detailing never And [ph]. we -- then much this the a cases. had -- the reach success

the So, I been think strong. very has physician response

Operator

Greg from with We Securities. our next question will Truist Fraser take

Greg Fraser

on reasons? Cortrophin. or you of filled, numbers? if patients therapy are of on for patient A on are couple what the those on many just quarter? scripts average being And written comment at the some Can And percentage that on the being are of are not the end Maybe the you then patients specifics the quarter that number are how filled. could that primary during provide therapy

Nikhil Lalwani

Got it.

and look So, -- Greg. you thank question, your for

our doubling for the on lives. progress look, case We've in XXX On that initiations gaining demand early also new initiations XXX so for than to Cortrophin Gel. good patients therapy, question has on we're made manual by encouraged coverage case million very of resulted more far by formulary physician

need patients currently Our in ambition that specific we're on terms for access north still at Cortrophin of on. obviously as we're that expand patients XXX to stands. on is of And significantly numbers therapy, patients it Gel therapy, working currently something of

Greg Fraser

it. Got

follow-ups. for for portion could lives you that couple of comment covered any target contract a to you million-plus so you’ve would that sort a be And helpful. from behavior Just What access? have covered of for reactionary have do And which on seen just if far looking that you’re access? then Mallinckrodt, lives favorable number advantaged XXX of

Nikhil Lalwani

Thanks, Yes. Greg.

Greg, expand or our to to Cortrophin very question? second you some of release. in patients is we've that But commenting recent from, that repeating on significantly lives. middle XXX coverage would shared as a want the many ambition something our for that we're good of information. you million expect, wins, advantaged and like I while we'd the we've getting is clear to And to great think said, one that of we our I need And for then, specifics will contracting, mind in And I in recent access be As of of made how the wins, targeted Gel. degree press this steer on progress highlighted specifics terms

Greg Fraser

Yes.

Just reactionary from Mallinckrodt. curious some if behavior you’ve seen

Nikhil Lalwani

to the Mallinckrodt of what to our company do providing that, focused happened what ACTH tracking another and purpose we therapy we're Look, But need we're more doing on to than have choice any achieve changes. Yes. and in at importantly that our is patients. the resulting changes

of are steroid As and indications mentioned a actually ACTH before, less who receive XX% therapy. resistant suggests epidemiology than primary across claims-based analysis patients refractory

So this need that focused is on. we're the unmet

Operator

[Operator Instructions] next Folkes will take question Brandon with Cantor our We from Fitzgerald.

Brandon Folkes

on And parts guidance just color results. prescribers? color to can the the that versus just the first-time coming half sort Maybe on us should you prescribers additional pace there? moving expect then Any think Congratulations of online of the in Cortrophin. there? about the the we raise, the patient coverage Do increase of ask X on starts you about year And split help -- one. think the new with ATCH-experienced the have I’ll back of by just guidance raise my better then, driven other you how

additional development business we of assets? generics terms bringing to additional assets? rare disease generic of bring do think of ANI growing business maybe forward, bring in to primary in you sort longer or the Just in assets in continue as or specialty driver should look term, Just going its

Nikhil Lalwani

Brandon, thank question. for Yes. you, And your

prescribers, the terms In new details we're sharing time. at prescribers not those of split experienced versus between this

or your and As share these there's context there. share imagine, you a not can here on competitive what we drives calls that understanding I can appreciate

is of it's get we Increase patients -- number as will so it that we patients both it's and does get driven And -- in Yes, there. the new not on drives the Regarding we that on therapy Cortrophin is increase. that and that by enrollments, both the go of see of increase therapy absolutely guidance guidance, of your forward number patient on raise the the in range in believe the right? inform increase factors, the initiated. new the question an acceleration guidance cases and the our second number and -- look, will on guidance that momentum

just last we've number doubled initiated said, I the since the new cases patient As of earnings.

bring unit We third those to have business as development, momentum expand And expect on rare absolutely in in the therapy. getting and as disease on your have. question patients assets use one we will is then, look, one invested we that to rare and that business continue, heavily that that the we additional platform well disease

platform Cortrophin unravel on this elements where There on in allocation will how move ANI as the Cortrophin think we rare be you that terms executing dosage capital look in the at source far bringing And Purified areas of potentially drive look that it a that R&D as and But and that – at And additional high-performing development that’s an targeted the we will Gel drive generics and about launch. are at Of course, rock that growth time, will be will focused as goes, forward. we're get of think there. many engine. disease launch other be to of assets solid, the of absolutely focused, organic business business where business look, forms, will we as I have is Gel other forward. the development

opportunistic chance to better where expand Of course, we portfolio. our are Oakrum Pharma-type acquisitions achieve the

Operator

from question with Raymond Elliot follow-up a have James. do Wilbur We

Elliot Wilbur

of on I a on settlement pipeline, [ph]. terms think your been also, specifically you in things And numbers if there’s in or at IV in where ANDAs quickly thinking of the Paragraph business. stand not reprostinil you don’t FDA. generic real but I just Just have wondering filing pending about number currently Nikhil, reached know front of

about of be couple acquisition, Just wondering in up you picked if when that can assets. you a opportunity. of And also anything able think there’s the part XXX(b)(X) terms of you as say I to that may monetize Novitium

Just wondering since there’s with what line anything you the time more say occurred If developments could those. acquisition. about associated the have

Nikhil Lalwani

question. your Elliot, for you, Thank Yes.

progressing I'm just multiple on had. It's assets the on assets, well. they're Or XXX(b)(X) So not X. we that XXX(b)(X) sorry, X well. the They're progressing

XXX(b)(X)s idea take forward. and one we'll the are on to calls. share have more engine of is the forward of that them I But Novitium launch think that R&D in We details the of we'll drive using significant and we to made something progress looking and future committed at

we XXX(b)(X)s. the domain. that not The than what’s on is the can in share one more on that's So settlement reprostinil public

ANDAs, terms So think is so are obviously, total number have well, – it’s in I But Elliot, that FDA. And close ANDAs number your think allow back it’s ANDAs. at pending, the something which then to I’ll to we to are you me I know the of have FDA. to as this question come pending number pipeline. third that of to you the total that of of steer is clear But XX at the the of keep the I adding that. the pending

high-performing number a number engine, have XX terms approvals ranked the ANDA X the months. in in R&D of received past We of

So that as to adding it’s keep imagine. something will the pipeline, we you

Operator

line our have at we appears this I over or program the on presenters back to questions for no any remarks. It closing further the turn additional time. will

Nikhil Lalwani

Thank turning joining potential morning. you, disease high-quality Yes. to and this everyone, our advancing R&D product, made call active lead engine much of medicines Gel, to rare delivering Thank you for remain need. date while continue capturing excellent to very Cortrophin patients our committed our the back. all the to full We’ve progress in call for

progress. we support our appreciate always, sharing and again the shareholders look and of future forward Thanks As well. our to stay

Operator

conclude you does This participation. today's program. for your Thank

and wonderful disconnect You time at may have a any day.

ANI Pharmaceuticals (ANIP) 8 Aug 222022 Q2 Earnings call transcript